eLearning library with a particular emphasis on Pharmaceutical Regulatory Affairs and Compliance within the pharmaceutical and biotechnology industries.
Ref.CC172
Location Re-locatable
Asking Price £ 1,600,000
Location Re-locatable
Asking Price £ 1,600,000
Business profile:
Introduction
Turner Butler has been appointed to invite offers of purchase for 100% of the Issued Share capital of a company that has developed an eLearning platform with a particular emphasis on Pharmaceutical Regulatory Affairs and Compliance within the pharmaceutical and biotechnology industries.
Key strengths:
The business has the following key attributes:
• Powerful eLearning platform with extensive library.
• Particular emphasis on Pharmaceutical Regulatory Affairs and Compliance within the pharmaceutical and biotechnology industries.
• Additional generic corporate eLearning programs and bespoke development capabilities.
• 25 courses representing approximately 55 hours of eLearning.
• Solid, longstanding international Client base including some of the biggest names in the pharmaceutical and biotechnology industries.
• Three year contracts in place with some Clients.
• Growth/niche business sector.
• Substantial potential for course and market expansion.
• Easily transportable, profitable business.
The business provides an acquirer with:
• An ideal bolt on for a company already providing eLearning.
• An excellent opportunity for any investor with a background in the IT or Pharmaceutical/Biotechnology industries.
Introduction
Turner Butler has been appointed to invite offers of purchase for 100% of the Issued Share capital of a company that has developed an eLearning platform with a particular emphasis on Pharmaceutical Regulatory Affairs and Compliance within the pharmaceutical and biotechnology industries.
Key strengths:
The business has the following key attributes:
• Powerful eLearning platform with extensive library.
• Particular emphasis on Pharmaceutical Regulatory Affairs and Compliance within the pharmaceutical and biotechnology industries.
• Additional generic corporate eLearning programs and bespoke development capabilities.
• 25 courses representing approximately 55 hours of eLearning.
• Solid, longstanding international Client base including some of the biggest names in the pharmaceutical and biotechnology industries.
• Three year contracts in place with some Clients.
• Growth/niche business sector.
• Substantial potential for course and market expansion.
• Easily transportable, profitable business.
The business provides an acquirer with:
• An ideal bolt on for a company already providing eLearning.
• An excellent opportunity for any investor with a background in the IT or Pharmaceutical/Biotechnology industries.
